Hints and tips:
...Banco Santander, BT Group, Centrica, CMC Markets, Co-operative Bank, CVS Group, Diageo, Enel, Hammerson, JCDecaux, L’Oréal, Leonardo, Nestlé, OMV, Orange, Relx, Rentokil Initial, Repsol, Royal Dutch Shell, Sanofi-Aventis...
...H1, Mastercard Q2, Merck & Co Q2, Nestlé H1, Nissan Motor Q1, Northrop Grumman Q2, OMV Q2, Orange H1, Panasonic Q1, Pfizer Q2, Relx H1, Rentokil Initial H1, Repsol Q2, Royal Dutch Shell Q2, Samsung Q2, Sanofi-Aventis...
...Markit construction PMI data US, monthly motor vehicle sales, payrolls and unemployment figures Results: Aon Q4, Bristol-Myers Squibb Q4, Carlsberg FY, Intesa Sanpaolo FY, Regeneron Pharmaceuticals Q4, Sanofi-Aventis...
...Q2 Mediobanca Q2 Merck & Co Q2 National Express H1 Nestle H1 Northrop Grumman Q2 Orange H1 Panasonic Q1 Pinterest Q1 Rentokil H1 Repsol Q2 Royal Dutch Shell Q2 Saint-Gobain H1 Samsung Q2 Sanofi-Aventis...
...After a spate of foreign takeovers of Indian drugmakers by companies such as Daiichi Sankyo, Sanofi-Aventis and Abbott Laboratories in the past decade, some policymakers demanded that pharmaceuticals be...
...Mr Miels started his pharmaceuticals career at AstraZeneca in 1995, leaving in 2000 for Sanofi-Aventis before joining Switzerland’s Roche in 2006, where he ran the company’s Asia business....
...While not seen in Germany before, Braas’s tactic has some similarities to that deployed by French drugmaker Aventis in 2004, in an attempt to avoid being acquired by Sanofi in a $60bn deal....
...Sanofi and Aventis merged to take on US pharma, but have not caught Pfizer. Nor have Glaxo and SmithKline Beecham....
...Later he was with Aventis, another Franco-German drugmaker, in the US when it merged with France’s Sanofi. His experience of these deals was mostly negative. “Sanofi-Aventis didn’t work,” he says....
...In Bayer’s case, the shift to life sciences started as long ago as 2001, when the group paid €7.25bn for Aventis CropScience in what was then its largest acquisition....
...In 1990, Aventis (a German pharmaceutical company acquired by Sanofi in 2004), registered a new injectable medicine called eflornithine, used for treating cancer and subsequently adapted as a cream to reduce...
...The business has a relationship with many of the big regional pharmaceutical companies, as well as some multinationals including French drugmaker Sanofi-Aventis....
...In the pharmaceuticals sector, the state engineered the merger between Sanofi and Aventis to create a new state champion rather than allow the Swiss Novartis to swallow up Aventis....
...His next stop was Aventis, which was bought by Sanofi, which had by then acquired Hoechst. “I’ve never said mergers should never happen,” he says. “But it depends how it is done....
...Expansion by larger drug companies was the norm at the start of this century, from the merger that created GlaxoSmithKline in 2000 and the $67bn purchase of Aventis by Sanofi in 2004, to Pfizer’s $68bn paid...
...Responding to a health ministry pledge to buy locally made medicines, pharmaceutical companies including Novartis and Sanofi-Aventis are building plants and R&D facilities....
...point it seemed Anudu’s future might be in academia, as he juggled a full-time job in research in Lagos, with the agrochemicals division of French chemicals and pharmaceuticals company Rhône-Poulenc (now Aventis...
...Among the stocks covered by the dividend futures contracts are Enel, Telecom Italia, UniCredit, Axa, GDF Suez, Sanofi-Aventis, Deutsche Bank and Siemens....
...Amgen, Sanofi-Aventis and Pfizer have all made acquisitions in this area in Brazil....
...Mr Soriot, 53, a Frenchman who trained as a veterinary surgeon before obtaining an MBA, worked for much of his career in Asia for Roussel Uclaf, Hoechst and Aventis, which became part of Sanofi in 2004....
...It was the largest bond sale in the US since March 2011, when Sanofi-Aventis sold $7bn, Dealogic said....
..., the French drugmaker, against a hostile takeover by rival Sanofi....
...For this reason, shares in GSK trade at about 11 times this year’s expected earnings, a little lower than Roche, but a premium of one-tenth to Novartis and one-third to AstraZeneca and Sanofi-Aventis....
...Novartis, Sanofi-Aventis and AstraZeneca announced research setbacks on new drugs. But it was the UK-based group’s admission that moved the market the most....
International Edition